Beam Therapeutics (BEAM) - Volume dana dhuwit perusahaan

BEAM (beamtx.com) - tandha merek perusahaan

Free cash flow demonstrates the financial resilience of Beam Therapeutics Inc. (BEAM), where the current figure stands at 1.04. Liquidity trends are critical, as the absence of commercial products leaves the company dependent on external financing and laboratory breakthroughs. Meanwhile, the business relies on licensing agreements with industry behemoths to advance high-precision genome editing, combining third-party manufacturing with the development of its own plant.

BEAM - Dhuwit awis perusahaan Beam Therapeutics Corp ing rentang 04.07.2022 - 21.11.2026

Rincian metrik keuangan lan pasar Beam Therapeutics (BEAM)

Analisis dhasar perusahaan:BEAM Beam Therapeutics
Sampel barang beamtx.com

Beam Therapeutics Inc. (BEAM) holds a leading position in the development of precision DNA editing, where liquidity is critical for funding the costly clinical trials of its "genetic eraser." By analyzing the cash reserve metric, an investor assesses the actual burn rate and the business's autonomy horizon, which allows for forecasting the risk of default or the necessity of a secondary offering prior to product commercialization.

Karo sapa Beam Therapeutics Inc. saingan

Volume dana dhuwit perusahaan TEM|QGEN - Cadangan dhuwit perusahaan|ionispharma.com - Dhuwit awis perusahaan|Sisa dhuwit perusahaan RGEN|Avidity Corp - Volume dana dhuwit perusahaan|CRISPR Therapeutics Corp - Gunggung dana dhuwit perusahaan|GeneDx Holdings (WGS) - Dana dhuwit perusahaan|Ultragenyx Pharmaceutical (RARE) - Volume dana dhuwit perusahaan|SRPT (Sarepta Therapeutics) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan Twist Bioscience Inc (TWST)|Volume dana dhuwit perusahaan TXG|Aset likuid perusahaan Intellia|Stoke - Dhuwit awis perusahaan|BLFS: Dhuwit awis lan setara dhuwit awis perusahaan|Wave Life Sciences Corp - Volume dana dhuwit perusahaan|Maze Therapeutics, Inc. (MAZE) - Dhuwit awis perusahaan|Sionna Therapeutics Inc (SION) - Dana dhuwit perusahaan|Dhuwit awis perusahaan Prime Medicine Corp|Dana dhuwit perusahaan tayshagtx.com|QURE - Posisi dhuwit perusahaan|Dhuwit awis perusahaan MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Posisi dhuwit perusahaan|Volume dana dhuwit perusahaan SLDB (Solid Biosciences Inc.)|Sisa dhuwit perusahaan OCGN|PacBio Corp - Volume dana dhuwit perusahaan|Benitec Biopharma Inc. (BNTC) - Dhuwit awis perusahaan|DSGN: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan RCKT|Dhuwit awis perusahaan FDMT|Dhuwit awis lan setara dhuwit awis perusahaan LXEO (Lexeo Therapeutics)|Volume dana dhuwit perusahaan KRRO|Editas Medicine, Inc. - Dhuwit awis lan setara dhuwit awis perusahaan|Dana dhuwit perusahaan Silence Therapeutics Inc. SLN|Volume dana dhuwit perusahaan ProQR Therapeutics N.V. PRQR|CDXS: Dhuwit awis perusahaan|Posisi dhuwit perusahaan Sangamo (SGMO)|NAUT (Nautilus Bio) - Dhuwit awis perusahaan|MGX - Aset likuid perusahaan|DTIL (Precision BioSciences Inc.) - Volume dana dhuwit perusahaan|generationbio.com (GBIO) - Aset likuid perusahaan|Dana dhuwit perusahaan Boundless Bio Inc (BOLD)|Volume dana dhuwit perusahaan Exicure Inc. (XCUR)|Dana dhuwit perusahaan imunon.com IMNN|Volume dana dhuwit perusahaan Phio Pharmaceuticals PHIO|Mustang Bio Inc - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan transcodetherapeutics.com|BNGO: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan APDN|BLUE (bluebirdbio.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan ImmunoPrecise Antibodies IPA|Dhuwit awis perusahaan OMGA (omegatherapeutics.com)|Volume dana dhuwit perusahaan Singular Genomics Systems, Inc. (OMIC)|Volume dana dhuwit perusahaan RGLS (Regulus Therapeutics, Inc.)|Volume dana dhuwit perusahaan Syros SYRS|Telesis Bio, Inc. - Volume dana dhuwit perusahaan|TRACON Pharmaceuticals (TCON) - Dhuwit awis perusahaan|UBX: Volume dana dhuwit perusahaan